Annovis Bio, Inc.
NYSE:ANVSBiotechnology
+$0.00 today
- Market cap
- $51.64M
- Beta
- 1.24
- P/E (TTM)
- -1.1
- EPS (TTM)
- -$1.47
Volume 1.35M
Average 1.08M
ANVS Net Debt
Total debt minus cash and equivalents; a negative value means the company holds more cash than debt.
Annovis Bio, Inc.NYSE: ANVS
Net Debt · Q1 FY2026 · quarter ended Mar 2026
Net debt remains negative
Q1 FY2026 net debt was -$14.22M, compared with -$22.24M a year earlier.
Context
- Net debt amounted to 87.5% of total assets at the end of Q1 FY2026, up 4.4 pp from a year earlier.
- Net debt grew in size in 2 of the last 3 fiscal years.
What to watch
Whether net debt keeps rising in the next quarterly balance sheet after a +36.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Debt history
USD · from the balance sheet
- Latest · FY2025
- (19.53M) USD
- Year-over-year change
- -85.1%
| Period | Period end | Net Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (19.53M) | -85.1% |
| FY2024 | 2024-12-31 | (10.55M) | -83.4% |
| FY2023 | 2023-12-31 | (5.75M) | +79.7% |
| FY2022 | 2022-12-31 | (28.38M) | +37.9% |
| FY2021 | 2021-12-31 | (45.69M) | — |
Net Debt vs competitors
How ANVS compares with its peers on the latest reported figures
- ANVS's Mar 2026 net debt of -$14.22M is the 4th highest of the 6 companies compared; the peer median is -$6.74M.
- Its year-over-year change of +36.1% is the 3rd highest of 6, against a peer median of -49.0%.
- Net debt amounts to 87.5% of total assets for ANVS, versus a peer median of 35.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Dec 2025 | $34.73M | -49.0% | -12.4% | 32.4% | |
| Mar 2026 | -$5.8M | +72.4% | — | 23.5% | |
| Mar 2026 | -$6.74M | -202.8% | — | 35.2% | |
| Mar 2026 | -$14.22M | +36.1% | — | 87.5% | |
| Mar 2026 | -$34.41M | -216.8% | — | 97.4% | |
| Jun 2026 | -$35.13M | +40.1% | — | 87.5% | |
| Peer median (excluding ANVS) | -$6.74M | -49.0% | -12.4% | 35.2% | |
Competitors are the stored peer set for ANVS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Annovis Bio, Inc.
NYSE:ANVS
Intrinsic Alpha fair value
Locked
Current Price
$1.21
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.